trial · primary record
Guselkumab
Psoriasis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2026-12-18 |
| Primary endpoint | Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 |
| Registry ID | NCT03451851 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:52.655Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03451851
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Guselkumab · approval
- Guselkumab · compound